- Home
- TE vs ELDN Comparison
TE vs ELDN Comparison
Compare TE & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TE
- ELDN
- Stock Information
- Founded
- TE N/A
- ELDN 2004
- Country
- TE United States
- ELDN United States
- Employees
- TE N/A
- ELDN N/A
- Industry
- TE
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- TE
- ELDN Health Care
- Exchange
- TE NYSE
- ELDN Nasdaq
- Market Cap
- TE 218.3M
- ELDN 178.4M
- IPO Year
- TE N/A
- ELDN N/A
- Fundamental
- Price
- TE $1.41
- ELDN $3.62
- Analyst Decision
- TE
- ELDN Strong Buy
- Analyst Count
- TE 0
- ELDN 2
- Target Price
- TE N/A
- ELDN $12.50
- AVG Volume (30 Days)
- TE 1.6M
- ELDN 880.0K
- Earning Date
- TE 08-11-2025
- ELDN 08-18-2025
- Dividend Yield
- TE N/A
- ELDN N/A
- EPS Growth
- TE N/A
- ELDN N/A
- EPS
- TE N/A
- ELDN N/A
- Revenue
- TE $67,589,000.00
- ELDN N/A
- Revenue This Year
- TE $34,332.36
- ELDN N/A
- Revenue Next Year
- TE $60.81
- ELDN N/A
- P/E Ratio
- TE N/A
- ELDN N/A
- Revenue Growth
- TE N/A
- ELDN N/A
- 52 Week Low
- TE $0.91
- ELDN $2.38
- 52 Week High
- TE $3.36
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- TE N/A
- ELDN 59.47
- Support Level
- TE N/A
- ELDN $3.63
- Resistance Level
- TE N/A
- ELDN $3.95
- Average True Range (ATR)
- TE 0.00
- ELDN 0.24
- MACD
- TE 0.00
- ELDN 0.01
- Stochastic Oscillator
- TE 0.00
- ELDN 49.73
About TE T1 ENERGY INC
T1 Energy Inc is an energy solutions producer of clean battery solutions. The company acts as a solar manufacturing company in the USA with complementary solar and battery storage.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.